<DOC>
	<DOC>NCT00154115</DOC>
	<brief_summary>Prospective, randomized, double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery. Study hypothesis: Levosimendan diminishes the need for adrenergic inotropic drugs and morbidity and may improve survival after heart valve surgery.</brief_summary>
	<brief_title>Levosimendan in High Risk Heart Valve Surgery</brief_title>
	<detailed_description>200 patients are prospectively randomized in a double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery. Levosimendan/placebo is administered as 24 hour continuous infusion beginning after anesthesia induction. Primary endpoint being adrenergic inotrope need after cardiopulmonary bypass and secondary endpoints hospital and 6-month mortality and major organ failure.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Eligible for cardiac valve or combined CABG and cardiac valve surgery: Clinical signs of cardiac insufficiency Endocarditis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>heart failure</keyword>
	<keyword>levosimendan</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>